Walgreens Boots Alliance is a global leader in retail and wholesale pharmacy, touching millions of lives every day through dispensing and distributing medicines, and through its convenient retail locations, digital platforms and health and beauty products. The company has more than 100 years of trusted health care heritage and innovation in community pharmacy and pharmaceutical wholesaling.
Including equity method investments, WBA has a presence in more than 25 countries, employs more than 450,000 people and has more than 21,000 stores.
WBA's purpose is to help people across the world lead healthier and happier lives. The company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. WBA is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business.
WBA is included in FORTUNE's 2020 list of the World's Most Admired Companies*, ranked first in the food and drugstore category. This is the 27th consecutive year that WBA or its predecessor company, Walgreen Co., has been named to the list.

Company profile
Ticker
WBA
Exchange
Website
CEO
Stefano Pessina
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Walgreen Arizona Drug Co. • Walgreens Boots Alliance Holdings LLC • Waltrust Properties, Inc. • Walgreens Specialty Pharmacy, LLC • Prime Therapeutics Specialty Pharmacy LLC • WBA Investments, Inc. • WBA Financial, LLC • Alliance Healthcare Deutschland AG • Walgreens Boots Alliance (Hong Kong) Investments Limited • Walgreen Co. ...
WBA stock data
News

Walgreens Contributed To Opioid Epidemic In San Francisco: Report
11 Aug 22
'Walgreens prescriptions added to opioid epidemic in San Francisco, judge finds' -Reuters
10 Aug 22
Looking Into Walgreens Boots Alliance's Recent Short Interest
9 Aug 22
10 Highest Yielding Dow Jones Stocks: Which Stocks Pay Out 3.2% To 5.5% To Investors?
2 Aug 22
Benzinga Pro's Top 5 Stocks To Watch For Monday, Aug. 1, 2022: SBUX, ADP, DG, RKDA, RAD
1 Aug 22
Press releases
HUGGIES® AND WALGREENS® ENCOURAGE PARENTS TO JOIN THEM IN SUPPORTING FAMILIES STRUGGLING WITH DIAPER NEED
1 Aug 22
Walgreens Boots Alliance Increases Quarterly Dividend
13 Jul 22
Thinking about trading options or stock in Nvidia, Walgreens Boots Alliance, Alibaba, Apple, or Walmart?
30 Jun 22
Walgreens Boots Alliance Reports Fiscal 2022 Third Quarter Results
30 Jun 22
Walgreens Now Providing Pfizer and Moderna COVID-19 Vaccines to Children Ages 3 and Older at Select Locations Nationwide
18 Jun 22
Analyst ratings and price targets
Current price
Average target
$42.86
Low target
$39.00
High target
$45.00
JP Morgan
Maintains
$45.00
Morgan Stanley
Maintains
$39.00
RBC Capital
Maintains
$42.00
Deutsche Bank
Maintains
$44.00
Truist Securities
Maintains
$42.00
Credit Suisse
Maintains
$43.00
Barclays
Maintains
$45.00
Calendar
30 Jun 22
12 Aug 22
31 Aug 22
Financial summary
Quarter (USD) | May 22 | Feb 22 | Nov 21 | Aug 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Aug 21 | Aug 20 | Aug 19 | Aug 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.54B | 4.54B | 4.54B | 4.54B | 4.54B | 4.54B |
Cash burn (monthly) | (no burn) | (no burn) | 106.67M | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 256.2M | n/a | n/a | n/a |
Cash remaining | n/a | n/a | 4.28B | n/a | n/a | n/a |
Runway (months of cash) | n/a | n/a | 40.2 | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Jul 22 | Brailer David J | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 37.24 | 805.585 | 30K | 63,995.81 |
13 Jul 22 | Lederer John Anthony | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 37.24 | 671.321 | 25K | 38,944.64 |
13 Jul 22 | Murphy Dominic | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 37.24 | 671.321 | 25K | 49,483.47 |
13 Jul 22 | Jarrett Valerie B | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 37.24 | 671.321 | 25K | 8,510 |
11 May 22 | Walgreens Boots Alliance | Common Stock | Sell | Dispose S | Yes | No | 150 | 6,000,000 | 900M | 52,854,867 |
Institutional ownership, Q1 2022
73.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1277 |
Opened positions | 98 |
Closed positions | 162 |
Increased positions | 553 |
Reduced positions | 424 |
13F shares | Current |
---|---|
Total value | 27.81B |
Total shares | 635.44M |
Total puts | 11.42M |
Total calls | 8.63M |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Alliance Sante Participations | 144.79M | $5.84B |
Vanguard | 59M | $2.64B |
BLK Blackrock | 57.75M | $2.59B |
STT State Street | 49.82M | $2.23B |
Capital World Investors | 21.5M | $962.73M |
FMR | 15.54M | $695.59M |
Geode Capital Management | 12.8M | $571.69M |
IVZ Invesco | 9.12M | $408.48M |
WFC Wells Fargo & Co. | 8.91M | $398.72M |
NTRS Northern Trust | 8.33M | $372.89M |
Financial report summary
?Risks
- Global health developments and economic uncertainty resulting from the COVID-19 pandemic have adversely impacted, and may continue to adversely impact, our business, results of operations, cash flows and financial position.
- Reductions in third-party reimbursement levels, from private or governmental agency plans, and potential changes in industry pricing benchmarks for prescription drugs could materially and adversely affect our results of operations.
- A shift in pharmacy mix toward lower margin plans, products and programs could adversely affect our results of operations.
- We derive a significant portion of our sales in the U.S. from prescription drug sales reimbursed by a limited number of pharmacy benefit management companies.
- We could be adversely affected by a decrease in the introduction of new brand name and generic prescription drugs as well as increases in the cost to procure prescription drugs.
- Consolidation and strategic alliances in the healthcare industry could adversely affect our business operations, competitive positioning, financial condition and results of operations.
- Our business results depend on our ability to successfully manage ongoing organizational change and business transformation and achieve cost savings and operating efficiency initiatives.
- Changes in economic conditions could adversely affect consumer buying practices.
- The industries in which we operate are highly competitive and constantly evolving and changes in market dynamics could adversely impact us.
- If we do not successfully develop and maintain a relevant omni-channel experience for our customers, our businesses and results of operations could be adversely impacted.
- If the merchandise and services that we offer fail to meet customer needs, our sales may be adversely affected.
- Our substantial international business operations subject us to a number of operating, economic, political, regulatory and other international business risks.
- Disruption in our global supply chain could negatively impact our businesses.
- We outsource certain business processes to third-party vendors that subject us to risks, including disruptions in business and increased costs.
- We use a single wholesaler of branded and generic pharmaceutical drugs as our primary source of such products.
- Failure to retain and recruit, or failure to manage succession of, key personnel could have an adverse impact on our future performance.
- We may be unable to keep existing store locations or open new locations in desirable places on favorable terms, which could materially and adversely affect our results of operations.
- Our business and operations are subject to risks related to climate change.
- We may not be successful in executing elements of our business strategy, which may have a material adverse impact on our business and financial results.
- Our growth strategy is partially dependent upon our ability to identify and successfully complete acquisitions, joint ventures and other strategic partnerships and alliances.
- The anticipated strategic and financial benefits of our relationship with AmerisourceBergen may not be realized.
- From time to time, we make investments in companies over which we do not have sole control and some of these companies may operate in sectors that differ from our current operations and have different risks.
- A significant disruption in our information technology and computer systems or those of businesses we rely on could harm us.
- We are subject to payment-related and other financial services risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and potentially disrupt our business operations.
- We have significant outstanding debt; our debt and associated payment obligations could significantly increase in the future if we incur additional debt and do not retire existing debt.
- As a holding company, we are dependent on funding from our operating subsidiaries to pay dividends and other obligations.
- Our quarterly results may fluctuate significantly based on seasonality and other factors.
- We have a substantial amount of goodwill and other intangible assets which could, in the future, become impaired and result in material non-cash charges to our results of operations.
- We are exposed to risks associated with foreign currency exchange rate fluctuations.
- We could be adversely impacted by changes in assumptions used in calculating pension assets and liabilities.
- Changes in the healthcare industry and regulatory environments may adversely affect our businesses.
- We are exposed to risks related to litigation and other legal proceedings.
- A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on our reputation and profitability.
- We could be adversely affected by violations of anti-bribery, anti-corruption and/or international trade laws.
- We could be adversely affected by product liability, product recall, personal injury or other health and safety issues.
- We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.
- Certain stockholders may have significant voting influence over matters requiring stockholder approval.
- Conflicts of interest, or the appearance of conflicts of interest, may arise because certain of our directors and officers are also owners or directors of companies we may have dealings with.
- Our certificate of incorporation and bylaws, Delaware law or our agreements with certain stockholders may impede the ability of our stockholders to make changes to our Board or impede a takeover.
- We cannot guarantee that our stock repurchase program will be fully implemented or that it will enhance long-term stockholder value.
Management Discussion
- The Company's United States segment includes the Walgreens business which includes the operations of retail drugstores, health and wellness services, and mail and central specialty pharmacy services, and its equity method investment in AmerisourceBergen. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise.
- WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
- 1See “Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
absence, admission, aforementioned, category, chain, composing, Computershare, conclusion, constitute, defense, escrow, exporting, Fargo, indenture, indirect, indirectly, inflow, judgement, modest, peak, penalty, permissible, pertaining, petition, remediation, renamed, restitution, satisfied, Sequoyah, Simultaneously, successor, unutilized, voluntary, Yen
Removed:
approach, continuation, European, execution, pandemic, Pasco, pretax, Union
Financial reports
Current reports
8-K
Walgreens Boots Alliance Reports Fiscal 2022 Third Quarter Results
30 Jun 22
8-K
Entry into a Material Definitive Agreement
21 Jun 22
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
3 Jun 22
8-K
Walgreens Reaches Opioid Settlement with State of Florida
4 May 22
8-K
Walgreens Boots Alliance Reports Fiscal 2022 Second Quarter Results
31 Mar 22
8-K
Departure of Directors or Certain Officers
2 Feb 22
8-K
Submission of Matters to a Vote of Security Holders
28 Jan 22
8-K
Walgreens Boots Alliance Exceeds Expectations for Fiscal 2022 First Quarter Earnings
6 Jan 22
8-K
Entry into a Material Definitive Agreement
26 Nov 21
8-K
Other Events
17 Nov 21
Registration and prospectus
S-3ASR
Automatic shelf registration
17 Dec 21
424B5
Prospectus supplement for primary offering
3 Nov 21
FWP
Free writing prospectus
2 Nov 21
424B5
Prospectus supplement for primary offering
2 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Feb 21
S-8
Registration of securities for employees
5 Feb 21
25-NSE
Exchange delisting
19 Oct 20
424B5
Prospectus supplement for primary offering
14 Apr 20
FWP
Free writing prospectus
13 Apr 20
Proxies
DEFA14A
Additional proxy soliciting materials
10 Jan 22
DEFA14A
Additional proxy soliciting materials
8 Dec 21
DEFA14A
Additional proxy soliciting materials
14 Jan 21
PX14A6G
Letter to shareholders
17 Dec 20
DEFA14A
Additional proxy soliciting materials
8 Dec 20
DEFA14A
Additional proxy soliciting materials
3 Jan 20
DEFA14A
Additional proxy soliciting materials
10 Dec 19
DEF 14A
Definitive proxy
10 Dec 19
Other
CERT
Certification of approval for exchange listing
21 Dec 18
UPLOAD
Letter from SEC
8 Apr 18
CORRESP
Correspondence with SEC
4 Apr 18
CORRESP
Correspondence with SEC
19 Mar 18
UPLOAD
Letter from SEC
4 Mar 18
NO ACT
No action letter
9 Oct 17
UPLOAD
Letter from SEC
20 Apr 17
CORRESP
Correspondence with SEC
11 Apr 17
CORRESP
Correspondence with SEC
23 Mar 17
UPLOAD
Letter from SEC
22 Feb 17
Ownership
SC 13D/A
AMERISOURCEBERGEN / Walgreens Boots Alliance ownership change
4 Aug 22
4
Walgreens Boots Alliance / VALERIE B JARRETT ownership change
15 Jul 22
4
Walgreens Boots Alliance / Dominic Murphy ownership change
15 Jul 22
4
Walgreens Boots Alliance / John Anthony Lederer ownership change
15 Jul 22
4
Walgreens Boots Alliance / DAVID J BRAILER ownership change
15 Jul 22
4
Change in insider ownership
13 May 22
SC 13D/A
AMERISOURCEBERGEN / Walgreens Boots Alliance ownership change
12 May 22
4
Walgreens Boots Alliance / James Kehoe ownership change
3 May 22
4
Walgreens Boots Alliance / DAVID J BRAILER ownership change
2 May 22
4
Walgreens Boots Alliance / VALERIE B JARRETT ownership change
2 May 22
Patents
Utility
Cosmetic skincare compositions
29 Mar 22
According to the present invention there is provided a cosmetic composition comprising: (i) a salicylic acid compound; (ii) monoammonium glycyrrhizate; and (iii) a polyphenolic antioxidant agent.
Utility
Cosmetic O/W Mascara Compositions Comprising Polyurethane Resin
3 Mar 22
According to the present invention there is provided a stable, fluid, tubing mascara composition in the form of an oil-water emulsion comprising: (i) at least 9% by weight of the total composition of one or more film-forming aliphatic polyurethane resins; and (ii) one or more waxes; wherein the ratio of total aliphatic polyurethane resin concentration to total wax concentration is between 0.70 and 0.92.
Utility
Skin care composition and method thereof
5 Oct 21
The disclosed technology relates to a composition comprising: 0.1 to 3 wt % (or 0.5 to 2.5 wt %) of a beta hydroxy acid, 0.05 to 3 wt % (or 0.09 to 2.5 wt %) of an O-substituted ascorbic acid or a derivative thereof, and a cosmetically acceptable medium comprising an aqueous phase, wherein a beta hydroxy acid is present at a higher concentration than O-substituted ascorbic acid or a derivative thereof.
Utility
Cosmetic Compositions
12 Aug 21
Inventors: Emma Billinger, David Fowler, Melanie Lewis
Utility
Cosmetic Preservative System
15 Jul 21
According to the present invention there is provided a cosmetic composition comprising a cosmetically acceptable carrier and a preservative system, wherein the preservative system comprises: (i) an antimicrobial agent; (ii) a chelating agent comprising ethylenediamine tetraacetic acid (EDTA) or a derivative thereof; and (iii) an antimicrobial booster agent selected from the group consisting of ethylhexylglycerin, caprylyl glycol, hydroxy acetophenone, caprylhydroxamic acid, phenethyl alcohol, p-anisic acid, glyceryl caprylate, levulinic acid, sodium levulinate, propanediol, hexanediol, pentylene glycol, capryloyl glycine, methylpropanediol, phenylpropanol, sodium anisate, and combinations thereof, wherein the antimicrobial agent is present in an amount of from about 0.001% to about 1% by weight of the composition.
Transcripts
2022 Q3
Earnings call transcript
30 Jun 22
2022 Q2
Earnings call transcript
31 Mar 22
2022 Q1
Earnings call transcript
6 Jan 22
2021 Q4
Earnings call transcript
15 Oct 21
2021 Q3
Earnings call transcript
1 Jul 21
2021 Q2
Earnings call transcript
31 Mar 21
2021 Q1
Earnings call transcript
7 Jan 21
2020 Q4
Earnings call transcript
15 Oct 20
2020 Q3
Earnings call transcript
9 Jul 20
2020 Q2
Earnings call transcript
2 Apr 20
Reddit threads
Today's pick
11 Aug 22
Bull Rally or Bull Trap?
10 Aug 22
What would your retirement portfolio be?
10 Aug 22
Market timers, this post is for you: the relative cheapness of value stocks is at historic levels, across the world. History suggests to buy.
9 Aug 22
Realistically, how many positions should I have?
2 Aug 22
$4397/year dividend income. What is your recommendation for % weight per stock? The goal is maximize dividend income w/o sacrifice quality. Thanks everyone!
2 Aug 22
Tech heavy portfolio with some divy growth. The plan is to keep increasing VOO until is 30% of portfolio, considering dropping Disney. Im trying to keep some growth but trying to balance. Im 22 btw.
2 Aug 22
How do you guys feel about WBA
2 Aug 22
r/Stocks Daily Discussion Monday - Aug 01, 2022
1 Aug 22
SCHD vs other div stocks I am considering buying for my kids (data from SeekingAlpha)
31 Jul 22